Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8–13 Weeks’ Gestation | Zendy

Pranav Pandya | Zendy; D. Wright | Zendy; Argyro Syngelaki | Zendy; Ranjit Akolekar | Zendy; K. H. Nicolaides | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8–13 Weeks’ Gestation

Author(s) -

Pranav Pandya,

D. Wright,

Argyro Syngelaki,

Ranjit Akolekar,

K. H. Nicolaides

Publication year - 2012

Publication title -

fetal diagnosis and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.976

H-Index - 60

eISSN - 1421-9964

pISSN - 1015-3837

DOI - 10.1159/000335684

Subject(s) - medicine , trisomy , gestation , obstetrics , gestational age , human chorionic gonadotropin , aneuploidy , placental growth factor , fetus , pregnancy associated plasma protein a , gynecology , pregnancy , prospective cohort study , population , down syndrome , first trimester , biology , biochemistry , genetics , environmental health , hormone , gene , chromosome , psychiatry , vascular endothelial growth factor , vegf receptors

To investigate whether measurement of maternal serum placental growth factor (PLGF) can improve the performance of first-trimester combined screening for trisomy-21 by fetal nuchal translucency (NT) thickness and serum free β-human chorionic gonadotropin (β-hCG) and PAPP-A.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research